THRIVE Drug Patent Profile
✉ Email this page to a colleague
When do Thrive patents expire, and when can generic versions of Thrive launch?
Thrive is a drug marketed by Glaxosmithkline Cons and is included in two NDAs.
The generic ingredient in THRIVE is nicotine polacrilex. There are thirty drug master file entries for this compound. Sixty suppliers are listed for this compound. Additional details are available on the nicotine polacrilex profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Thrive
A generic version of THRIVE was approved as nicotine polacrilex by P AND L on March 15th, 1999.
Summary for THRIVE
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 2 |
Clinical Trials: | 45 |
Formulation / Manufacturing: | see details |
DailyMed Link: | THRIVE at DailyMed |
Recent Clinical Trials for THRIVE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Imperial College London | Phase 4 |
Vir Biotechnology, Inc. | Phase 1/Phase 2 |
Pia Wintermark | Phase 1 |
Anatomical Therapeutic Chemical (ATC) Classes for THRIVE
US Patents and Regulatory Information for THRIVE
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Glaxosmithkline Cons | THRIVE | nicotine polacrilex | GUM, CHEWING;BUCCAL | 077658-001 | Jun 19, 2007 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Glaxosmithkline Cons | THRIVE | nicotine polacrilex | GUM, CHEWING;BUCCAL | 077656-001 | Jun 19, 2007 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |